AGTC Genomics Launches DPYD Genotyping Test to Enhance Safety and Personalization of Fluoropyrimidine Cancer Therapy

AGTC Genomics, a CAP-accredited precision medicine laboratory, is proud to announce the launch of its DPYD Genotyping Test, an advanced pharmacogenomics assay designed to identify patients at increased risk of severe toxicity from fluoropyrimidine-based chemotherapy, including 5-fluorouracil (5-FU), capecitabine, and tegafur.

Fluoropyrimidines remain among the most commonly prescribed chemotherapy drugs worldwide and are widely used in the treatment of colorectal, gastric, pancreatic, breast, and several other cancers. However, a significant proportion of patients carry genetic variants in the DPYD (Dihydropyrimidine Dehydrogenase) gene that impair the body's ability to metabolize these drugs safely.

Patients with reduced DPD enzyme activity may experience severe and potentially life-threatening toxicities, including neutropenia, severe diarrhea, mucositis, neurotoxicity, hospitalization, and treatment-related mortality.

Advancing Precision Oncology Through Pharmacogenomics

The newly launched DPYD Genotyping Test utilizes next-generation sequencing (NGS) technology to comprehensively evaluate clinically relevant DPYD variants associated with fluoropyrimidine metabolism. The test enables oncologists to identify at-risk patients before treatment initiation and personalize chemotherapy dosing according to internationally recognized clinical guidelines.

“Every cancer patient deserves the safest and most effective treatment possible,” said Prof. Dr. Chee-Onn Leong, Founder and CEO of AGTC Genomics.

“DPYD genotyping represents one of the most clinically actionable pharmacogenomic tests available today. By identifying patients with reduced DPD activity before therapy begins, clinicians can optimize treatment strategies, reduce avoidable toxicities, and improve patient outcomes.”

Supporting International Clinical Guidelines

Leading international organizations, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and various oncology societies, recommend consideration of DPYD testing before initiating fluoropyrimidine therapy.

The AGTC Genomics DPYD Genotyping Test provides actionable clinical information that helps clinicians:

• Identify patients at risk of severe fluoropyrimidine toxicity

• Support CPIC-guided dose adjustments

• Personalize chemotherapy regimens

• Reduce treatment-related complications

• Improve treatment tolerability and patient safety

• Enhance precision oncology decision-making

Comprehensive Variant Coverage

The assay covers a broad panel of clinically relevant DPYD variants, including key loss-of-function and decreased-function alleles associated with DPD deficiency. Results are interpreted by experienced molecular scientists and provided with clinically actionable recommendations to support treatment planning.

Accessible Testing for Oncology Centers Nationwide

The test is available to hospitals, oncology clinics, and healthcare providers throughout Malaysia. Samples can be collected using either 3–5 mL EDTA whole blood.

Testing is performed entirely within AGTC Genomics' CAP-accredited laboratory, ensuring high-quality standards, rapid turnaround times, and local clinical support.

Strengthening Precision Medicine in Malaysia

The launch of the DPYD Genotyping Test reflects AGTC Genomics’ ongoing commitment to making precision medicine more accessible and affordable in Malaysia and the region. By integrating pharmacogenomics into routine oncology care, AGTC Genomics aims to empower clinicians with evidence-based tools that improve patient safety while maximizing therapeutic benefit.

---

About AGTC Genomics

AGTC Genomics is a leading precision medicine and genomics company specializing in next-generation sequencing (NGS), pharmacogenomics, oncology genomics, hereditary disease testing, liquid biopsy, and multi-cancer early detection technologies. The company operates one of Malaysia’s most advanced clinical genomics laboratories and is committed to advancing personalized healthcare through innovation, research, and clinical excellence.